title: Cysteinyl leukotrienes in allergic inflammation: strategic target for therapy.
abstract: Systemically bioavailable leukotriene receptor antagonists (LTRAs) can reduce the essential components of allergic inflammation in allergic rhinitis (AR) and asthma by blocking cysteinyl leukotriene (CysLT) activity, resulting in a wide range of clinical effects. CysLTs, mediators, and modulators in the pathophysiology of asthma and AR are a key target for therapy because they modulate production of hemopoietic progenitor cells, survival and recruitment of eosinophils to inflamed tissue, activity of cytokines and chemokines, quantity of exhaled NO, smooth-muscle contraction, and proliferation of fibroblasts. The mechanism of action of LTRAs leads to their effects on systemic allergic inflammatory processes.
authors.affiliation: University of Wisconsin, Madison Medical School, Department of Medicine, 15/220 Clinical Science Center, 600 Highland Ave, Madison, WI 53792-2454, USA. wwb@medicine.wisc.edu
authors.forename: William
authors.initials: W
authors.lastname: Busse
authors.forename: Monica
authors.initials: M
authors.lastname: Kraft
mesh_terms: D000328:Adult; D002648:Child; D003545:Cysteine / Q000037:antagonists & inhibitors* / Q000276:immunology*; D006801:Humans; D006967:Hypersensitivity / Q000188:drug therapy* / Q000235:genetics / Q000276:immunology*; D018836:Inflammation Mediators / Q000037:antagonists & inhibitors* / Q000276:immunology*; D015289:Leukotrienes / Q000276:immunology*; D010641:Phenotype; D011788:Quality of Life; D012221:Rhinitis, Allergic, Perennial / Q000188:drug therapy* / Q000235:genetics / Q000276:immunology*
chemical_list: D018836:Inflammation Mediators; D015289:Leukotrienes; C112381:cysteinyl-leukotriene; D003545:Cysteine